SPOTLIGHT -
May 6th 2024
Significant findings included a 100% biochemical recurrence-free rate at 24 months post-surgery in patients with high-risk localized prostate cancer.
April 26th 2024
Melton, VP of scientific operations and development at Slope, discusses how new technologies can be used to ensure data is accurate.
April 25th 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics, provides a look into the potential of further indications for Coya 302 amid promising ALS study.
April 22nd 2024
Alder, CEO of Gain Therapeutics, discusses how the Magellan platform was used in the creation of GT-02287.
April 18th 2024
According to results of the study, 46% of patients with giant cell arteritis administered Rinvoq achieved sustained remission from weeks 12 to 52.
Polish Bid for Biotech Glory
Poland's government is aiming to make the Eastern European country a biotech powerhouse.
Government: Big Pharma's Best Friend in Emerging Markets?
To gain market access in emerging markets, pharma companies face pressure to offer a convincing Corporate Value Proposition to governments.
Does Your Portfolio Review Reflect What the Patient Really Wants?
The quest for 'radical' R&D innovation is often pursued at the expense of treatments with hidden blockbuster potential, writes Bert Spilker.
The Italian's Job
After his predecessor and countryman left the EMA in disgrace, Guido Rasi jumps in as executive director-with great challenges ahead.
Profound Changes in the Outsourcing Landscape
Sponsor sourcing requirements are diverging from the operating needs and long-term strategies of the major CROs.
Brand Success: It's Not Serendipity
A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.
Henry Waxman: "Representing" Healthcare to the Fullest
Henry Waxman, Congressional Representative from Los Angeles, California
Patient Advocacy: The Last 30 Years
The rise of advocacy groups has helped patients find their voice, but the power to change health profiles remains an elusive goal.
Henry Grabowski: Academia Sweet Spot
Henry Grabowski, PhD, Professor of Economics, Duke University
The Power of Observation
Observational studies present a compelling real-world corollary to the classic randomized clinical trial.
Cure for the Common Cold Chain Break
In medicines, as in life, the journey is just as important as the end result
Battles over Biosimilars
Sponsors must handle interchangeability, exclusivity, cost and coverage hurdles to win biosimilars game
Should Pharma Invest in R&D or Search for External Drug Candidates?
Find out how pharma can find new drug candidates and refill the pipeline in this episode of Pharma Faceoff. Watch now.
To Genzyme, Quality Data Depends on Quality Governance
The payoff is superior performance in key areas such as clinical trials
Challenges, Changes, Commitments
The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
To Align an Audience, Find a Pulse
All this uncertainty at the back end of drug development is a drain on future therapeutic progress against disease. It's a job killer, too.
The Next Wave: Pharm Exec's 2011 Pipeline Report
42 of the best new drugs in development–or parked at the FDA
Knowledge-Based Outsourcing: Driving Deeper Insights
Tracking, monitoring, and trend evaluation is not enough. Companies must now do more than assess what happened and why.
Learning to Succeed on the Job
Innovating in R&D may not be such a complicated task. Consumers simply want to find the product that gets a job done right every time
Is There a Balm for Gilead?
A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days?
Explaining the Drug Drought
Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development
Looking Beyond the Patent Cliff
Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP
Pharm Exec's Ninth Annual Industry Audit
Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond
EGA Talks Biosimilars
The European Generic Medicines Association's Director for Scientific Affairs, Suzette Cox, talks to us about the environment for biosimilars.
Patent Cliff Pushes Pharma to the Brink
May 24, 2010.
Managing the Three Drivers of Risk in Drug Development
Re-examining service provider roles can bring safety and speed on the road to registration.
Brave Neuro World
Cognitive enhancement is a $20 billion market of aging Boomers, cramming students, global travelers, and battling soldiers. What's pharma going to do about it.
The Race Is On
Several leading pharmas may already have a drug for a retrovirus linked to chronic fatigue disease. Has medicine's "problem child" finally earned the industry's respect?
Finding the Sweet Spot
How proper site activation and site enrollment can help you get the most from clinical trials.
How Evidence Based Medicine is Impacting Global Clinical and Reimbursement Practices
Evidence-based medicine is fast becoming one of the key concepts in clinical and reimbursement practices in the developed world